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Letter of reply to comments on our paper “A prospective randomized
comparison of neoprene vs thermoplast hand-based thumb spica
splinting for trapeziometacarpal arthrosis”Dear Editor,
We appreciate the interest in our work. Concern is expressed
about the high drop out rate, lack of radiological diagnosis, short-
term evaluation time, handling of missing data, and imprecise
splint wear instructions. We agree that our data should be inter-
preted in light of these aspects of the study design and execution.
This was a pragmatic clinical trial. We compared the effective-
ness of prescribing one of two treatments to the typical patient
who would receive that treatment in practice1,2. Pragmatic trials
don’t measure the efﬁcacy of a treatment under ideal conditions
(e.g., all patients wore the splint exactly as prescribed and had no
other conditions or treatments). Pragmatic trials test the effective-
ness of treatments as actually used in clinical practice in the
average patient, many of whom have other conditions and receive
other treatments. It is our routine practice to assess our estimates of
attrition at the halfway point of our prospective protocols and
recalculate power according to the true attrition rates. In practice
we diagnose trapeziometacarpal (TMC) arthrosis based on symp-
toms and physical examination, therefore we did not require radio-
graphs to conﬁrm the diagnosis. In our opinion, patients can tell
whether a splint helps relieve their symptoms within 4e6 weeks
of starting to use it. Also, given that there are no known disease-
modifying treatments for osteoarthritis, we consider the splints
palliative at best (for instance, we are not concerned about whether
a splint can affect joint alignment) and we advise patients to use
the splint for comfort at their discretion and do not give them spe-
ciﬁc instructions for wear of the splint. The randomization should
create comparable cohorts with no need to cross over and give
each patient a chance with each splint. Caregivers that believe it’s
important to prescribe a more detailed and speciﬁc set of instruc-
tions for splint wear, or that a speciﬁc subset of patients with
TMC arthrosis beneﬁt from splint wear, can readily repeat our study
with slight modiﬁcation.
Fifteen patients (24%) had an average improvement of 23  13
points (range, 10e57) with the use of a splint. There were six
DASH questionnaires (ﬁve at enrollment [8.1%] and one at
follow-up [1.6%]) with four or ﬁve missing items that were
analyzed. We used these DASH questionnaires with up to ﬁveDOI of original article: http://dx.doi.org/10.1016/j.joca.2013.12.025.
http://dx.doi.org/10.1016/j.joca.2014.02.001
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items did not represent more than 17% of the total 30 items of the
questionnaire.
We welcome additional investigation on splint treatment of
TMC arthrosis. In our opinion, additional pragmatic trials are likely
to conﬁrm the ﬁndings of our study that: (1) a large percentage of
patients with a new diagnosis of TMC arthrosis never return to the
ofﬁce after prescription of a splint even if they are enrolled in a clin-
ical trial; (2) splints (no matter the design or wear schedule) don’t
provide much pain relief or decrease in disability on average; and
(3) a relatively ﬂexible prefabricated splint is as good as a custom
rigid splint and slightly preferred.
A prefabricated splint for TMC arthrosis can be purchased at
the local pharmacy for roughly the cost of a single insurance
co-payment for visiting an occupational, physical, or certiﬁed
hand therapist’s ofﬁce. If we put ourselves in the patient’s
shoes, that seems like a reasonable option. An option worth
studying.
Sincerely,
Stéphanie J.E. Becker, MD
David Ring, MD, PhD
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